by
Lauren Dubinsky, Senior Reporter | May 10, 2018
BWXT's new medical isotope technology
BWX Technologies has developed a new technology to manufacture Mo-99 that uses neutron capture.
“While neutron capture was the original method for producing Mo-99, Tc-99m generators using neutron capture Mo-99 historically produced a far less concentrated elution of Tc-99m,” Dr. Jonathan Cirtain, VP of advanced technologies at BWXT, told HCB News. “Therefore, [it] limited the types of kits and doses of imaging agent that could be effectively compounded, administered and imaged.”
However, the new technology produces a proprietary Mo-99 product that when eluted, produces an eluent of similar specific activity to fission-based Tc-99m generators that are available today. That means radiopharmacies can use BWXT Tc-99m generators in the same way they use current fission-based Tc-99m generators.

Ad Statistics
Times Displayed: 2548
Times Visited: 12 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
But Cirtain noted that unlike the traditional process of producing Mo-99 and Tc-99m generators from a nuclear fission process, this process doesn’t use fission. As a result, it doesn’t produce uranium or other fission products as waste, which is costly and difficult to dispose of and can be a proliferation concern.
BWXT expects this new medical isotope technology to provide a reliable domestic supply of Mo-99 and Tc-99m for North America. But the company has competition from a handful of companies with the same goal.
“We are confident because we have experience in this area developed over decades of work, and we’ve had a highly successful development program, including supplemental assistance from outside expertise when needed,” said Cirtain.